Safety & Efficacy of Qurs e Fishar in Mild to Moderate Hypertensive Patients in Pakistan

NCT06852079 | Recruiting Phase 3 DMC

• 1 other identifier: QF-HLWP
• Study Type: interventional
• Target: 119
• Locations: 1 country
• Sites: 1

Brief Summary

The herbal medicine Qurs-e-Fishar to treat mild to moderate High blood pressure or hypertension comprises of Rauwolfia serpentina. A product of Hamdard Laboratories (Waqf) Pakistan. A Phase III Safety \& Efficacy Open-label, Single-Arm, Interventional, Multicenter, Study in mild to moderate hypertensive, adults (30 to 60 years of age) prescribed with study product for 12 weeks (84 days). Primary End Points:

1. 1.Reduction in diastolic blood pressure less than 130 / 80 mmHg at the end of the study period (accepted by WHO) or if there was a fall of 20 / 10 mmHg or more in diastolic blood pressure as compared to baseline.
2. 2.Type, frequency and severity of ADRs during the study period.

Conditions

Hypertension

Keywords

HTN; Hypertension; Qurs e Fishar

Outcome Measures

Primary Outcomes (1)

• Blood Pressure

  Blood pressure (in mmHg) will be measure at baseline and again at first follow-up (4th week), than at second follow-up (at 8th week) the end of treatment (12th week).

  12 weeks

Study Arms (1)

Effect of Qurs e Fishar on Hypertension

EXPERIMENTAL

Other: Qurs e Fishar

Interventions

Qurs e Fishar OTHER

Qurs e Fishar is a herbal remedy for Hypertension

Effect of Qurs e Fishar on Hypertension

Eligibility Criteria

• Age: 30 Years - 60 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• Ability to sign ICD
• Participant(s) are willing and able to fulfill the requirements of the study protocol
• Mild to moderate hypertensive
• Mild hypertension range (140-159/90-99 mm Hg)
• Moderate hypertension range (160-179/100-109 mm Hg)
• Be between the age of 30 to 60 year

You may not qualify if:

• Patients with recent history of following will be excluded:
• Severe hypertension,
• Congestive cardiac failure,
• Left ventricular failure,
• Myocardial ischemia,
• Renal failure or
• Cerebrovascular accidents

Sponsors & Collaborators

• Abdul Bari: lead
• Hamdard University: collaborator

Study Sites (1)

Taj Medical Complex, Hamdard University Hospital

Karachi, Sindh, Pakistan

RECRUITING

MeSH Terms

Conditions

Hypertension

Condition Hierarchy (Ancestors)

Vascular Diseases; Cardiovascular Diseases

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Co-Principal Investigator

Study Record Dates

• First Submitted: February 24, 2025
• First Posted: February 28, 2025
• Study Start: December 23, 2023
• Primary Completion: June 30, 2025
• Study Completion: December 31, 2025
• Last Updated: February 28, 2025

Record last verified: 2025-02

Data Sharing

• IPD Sharing: Will not share

Locations

PA (1)